Tuesday 17 November 2026
Export KYNB’s income statement to Excel — free account
Kyntra Bio Inc
KYNBKyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.
- Revenue
- n/m
- EPS
- n/m
- Free cash flow
- n/m
Quarter to June 2026, against a year earlier
3.11
0.33
−9.59%
Follow KYNB
Alert me
Where the cash went Twelve months to 30 June 2026
Free cash flow was −$38.1M: capital expenditures were more than operating cash flow. Cash fell by $69.2M. Lines the picture does not name came to −$87.3M. What is a cash flow statement?
- Free cash flow
- −$38.1M
- Returned to shareholders
- $0.00
- Debt, net
- $0.00 borrowed
- Change in cash
- −$69.2M over the period
| Operating cash flow | 0.0 |
|---|---|
| Free cash flow | 0.0 |
| Acquisitions, net | +0.1 |
| Into investments, net | 0.0 |
| Other | −0.1 |
| Change in cash | −0.1 |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Net Income |
183.19 | 163.62 | 183.45 | 215.65 |
+8 more TTM periods Free account |
Depreciation & Amortization |
(0.14) | 0.17 | 0.68 | 1.09 | |
Non Cash Items (Other) |
(70.29) | (38.06) | (35.87) | (37.69) | |
Accounts Receivable Change |
0.33 | (4.21) | (2.54) | 6.77 | |
Change in inventories |
1.51 | 2.86 | 5.36 | 9.75 | |
Accounts Payable Change |
(2.20) | (1.54) | (27.65) | (3.09) | |
Change in payables and accrued liability |
(11.05) | (16.93) | (45.51) | (117.02) | |
Change in other assets and liabilities |
(139.40) | (127.30) | (82.69) | (92.37) | |
Operating Cash Flow |
(38.05) | (21.38) | (4.77) | (16.91) | |
Capital expenditures |
— | — | (0.04) | 0.03 | |
Net Aquisitions |
100.55 | 96.53 | 96.59 | 91.42 | |
Short Term Investments Change (Net) |
(76.16) | (72.21) | (61.16) | (3.03) | |
Long-Term Investments Change (Net) |
33.42 | 88.04 | — | — | |
Other investing activities |
48.34 | — | — | — | |
Investing cash flow |
56.14 | 38.45 | 35.42 | 88.85 | |
Repayment/Issuance of Debt (Net) |
— | — | (80.56) | (80.56) | |
Other financial activities |
(5.38) | (5.39) | (5.47) | (5.47) | |
Financing cash flow |
(85.94) | (85.95) | (86.03) | (86.01) | |
Exchange Rate Adjustment |
(1.34) | (0.33) | 1.08 | 1.04 | |
Change in Cash |
(69.20) | (69.20) | (54.31) | (13.03) | |
Beginning Cash |
47.87 | 47.87 | 102.18 | 102.18 | |
Ending Cash |
(21.32) | (21.33) | 47.87 | 89.15 | |
Stock Based Compensation |
3.99 | 4.88 | 6.58 | 5.57 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
(150.82) | (147.11) | (153.03) | (195.97) | |
Investments Change (Net) |
(44.40) | (56.42) | (59.50) | 70.87 |
In millions of $ except per-share values · columns are period end dates · fundamentals updated 25 Oct 2026